acc (Proteintech)
Structured Review

Acc, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 214 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acc1/ACC1+Antibody/pmc13657224-175-56-57
Average 96 stars, based on 214 article reviews
Images
1) Product Images from "CCR5 protects against permanent brain ischemia by suppressing neuronal ferroptosis through AMPK/ACC signaling"
Article Title: CCR5 protects against permanent brain ischemia by suppressing neuronal ferroptosis through AMPK/ACC signaling
Journal: Neurotherapeutics
doi: 10.1016/j.neurot.2026.e01088
Figure Legend Snippet: AMPK inhibition completely abolishes CCR5-mediated GPX4 maintenance and anti-ferroptotic protection. (A–B) SH-SY5Y cells were treated with the AMPK inhibitor Compound C (COC, 10 μM) and cultured under hypoxia-ischemia-mimicking conditions. Representative western blots (A) and quantitative analyses (B) of phosphorylated AMPK (p-AMPK), total AMPK, phosphorylated ACC (p-ACC), total ACC, and the corresponding phosphorylation ratios were shown. (C–E) Under the same experimental conditions, representative western blots (C) and quantitative analyses (D) of CCR5 and GPX4 protein expression, together with MDA levels (E), were shown. β-Tubulin or β-actin were used as a loading control. Data are presented as mean ± SD (n = 3). Statistical analyses were performed using one-way ANOVA followed by Fisher's LSD post hoc tests. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Techniques Used: Inhibition, Cell Culture, Western Blot, Phospho-proteomics, Expressing, Control
Related Articles
other:Article Title: Design and synthesis of novel ATP-citrate lyase inhibitors and their effects on MAFLD/MASH. Article Snippet: ATP-citrate lyase (ACLY) has emerged as a promising therapeutic target for metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH).. Inspired by the common pharmacophore of natural ACLY inhibitors, we designed and synthesized a novel series of chalconeskeleton derivatives.. Extensive structure-activity relationship (SAR) studies revealed that introducing conformational constraint, particularly through five-membered ring formation (e.g., compound B1) or a rigid benzofuran scaffold (e.g., compound C1), remarkably enhanced ACLY inhibition. Article Title: Integrated Proteomics and Metabolomics Reveal the Direct Hepatic Protection of Propionate Against Alcoholic Liver Disease via the RGN-PPARα Pathway. Article Snippet: Primary antibodies, including β-actin (#66009-1-Ig), CPT1A (#15184-1-AP), SREBP-1 (#14088-1-AP), ACC1 (#21923-1-AP), ACOX1 (#83731-2-RR), PPARα (#66826-1-Ig) and Article Title: Integrated Proteomics and Metabolomics Reveal the Direct Hepatic Protection of Propionate Against Alcoholic Liver Disease via the RGN-PPARα Pathway Article Snippet: Primary antibodies, including β-actin (#66009-1-Ig), CPT1A (#15184-1-AP), SREBP-1 (#14088-1-AP), ACC1 (#21923-1-AP), ACOX1 (#83731-2-RR), PPARα (#66826-1-Ig) and Article Title: Ganoderic Acid A Alleviates NAFLD by Facilitating PPARα-CPT1A Complex and Enhancing Gut Microbiota Diversity Article Snippet: Proteins were transferred to PVDF membranes at a constant current of 250 mA for 2 hours using a transfer apparatus from DLAB Scientific Co., Ltd (Cat#18901229). Incubation:Article Title: Macrophage-derived IL-6 reprograms lipid metabolism to promote colorectal cancer development through USP14-mediated FASN deubiquitination Article Snippet: The proteins were transferred to PVDF membranes (Cat#03010040001; Merck Millipore, Massachusetts, USA). .. The membranes were blocked in TBST containing 5% nonfat milk for 1 h at room temperature and incubated overnight with primary antibodies against FASN (Cat#10624-2-AP, Proteintech), USP14 (Cat#14517-1-AP, Proteintech), SREBP1 (Cat#14088-1-AP, Proteintech), |

